Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

HCV NS3-4A protease

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV (19) HCV Protease (28) Bacterial (1) BCRP (1) Dengue Virus (1) DNA/RNA Synthesis (4) Drug Derivative (1) Flavivirus (1) HBV (1) Isotope-Labeled Compounds (3) P-glycoprotein (1) Ras (1) Reference Standards (5) SARS-CoV (14)
By Research Areas:	Cancer (3) Infection (29) Inflammation/Immunology (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: HCV Protease HCV Virus Protease HIV Protease Protease Activated Receptor (PAR) ClpP TMPRSS6 Calpain Serpin Enteropeptidase Ser/Thr Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17634

Glecaprevir 5+ Cited Publications ABT-493	HCV HCV Protease SARS-CoV	Infection
Glecaprevir is a novel **HCV NS3/4A protease inhibitor, with IC₅₀ values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀** of 4.09 μM .

HY-10241

Simeprevir Maximum Cited Publications 45 Publications Verification TMC435; TMC435350	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10235

Telaprevir 40+ Cited Publications VX-950	HCV Protease HCV SARS-CoV	Infection
Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the **HCV NS3-4A protease, the steady-state inhibitory constant (K_i*) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease* domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-12594

Paritaprevir 10+ Cited Publications ABT-450; Veruprevir	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-19840

Voxilaprevir GS-9857	HCV Protease	Infection Cancer
Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of **HCV NS3/4A protease** inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with K_i values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .

HY-10238

Danoprevir 15+ Cited Publications ITMN-191; R7227; RO5190591; RG7227	HCV Protease HCV SARS-CoV	Infection
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM) . Danoprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 0.05 μM .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-10243

Vaniprevir MK-7009	HCV HCV Protease	Infection
Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

HY-109571

HZ-1157	Flavivirus Dengue Virus HCV Protease	Infection Inflammation/Immunology
HZ-1157 inhibits **HCV NS3/4A protease with an IC₅₀** of 1.0 μmol/L. HZ-1157 (4a) has a high dengue virus inhibitory activity (EC₅₀ = 0.15 μM) and is a relatively nontoxic (CC₅₀ > 10 μM) dengue antiviral agent .

HY-14404

MK-1220	HBV HCV Protease	Infection
MK-1220 is a covalently reversible inhibitor of the hepatitis C virus (HCV) NS3/4A protease (NS3/4A *protease) with a K_i* of 0.02 nM. MK-1220 in cell models simulating viral replication exhibits EC₅₀s of 4 (with 10% fetal bovine serum) and 11 nM (50% normal human serum). MK-1220 can be used for the study of chronic hepatitis C virus infection .

HY-10241A

Simeprevir sodium TMC435 sodium; TMC435350 sodium	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-17634R

Glecaprevir (Standard) ABT-493 (Standard)	HCV HCV Protease SARS-CoV Reference Standards	Infection
Glecaprevir (Standard) is the analytical standard of Glecaprevir. This product is intended for research and analytical applications. Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 4.09 μM .

HY-19557

IDX-320	Drug Derivative HCV Protease	Infection
IDX-320 is a Pipecolic acid (HY-Y0669) derivative. IDX-320 inhibits NS3/4a proteases across genotypes 1a, 1b, 2a, and 4a with an IC₅₀ 0.8-1.9 nM. IDX-320 can be used in the research of HCV infection .

HY-10241S

Simeprevir-13C,d3 TMC435-¹³C,d₃; TMC435350-¹³C,d₃	Isotope-Labeled Compounds HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10235S

Telaprevir-d4 VX-950-d₄	Isotope-Labeled Compounds HCV Protease HCV SARS-CoV	Infection
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-16773

Vedroprevir GS-9451	HCV Protease BCRP P-glycoprotein	Infection
Vedroprevir (GS-9451) is an inhibitor for **HCV NS3/4A protease with an IC₅₀ of 3.2 nM. Vedroprevir is also an inhibitor for breast cancer resistant protein (BCRP) with an IC₅₀ of 1.4 μM. Vedroprevir inhibits P-gp, MRP1 and MRP2 with IC₅₀** of 34, 14.9 and 12 μM, respectively. Vedroprevir exhibits good pharmacokinetic characteristics in rats and dogs .

HY-131905S

BMS-986144	Isotope-Labeled Compounds HCV Protease HCV	Infection Inflammation/Immunology Cancer
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

HY-19932

MK-2748	HCV Protease HCV	Infection
MK-2748 is a hepatitis C virus (HCV) *NS3/4a* protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection .

HY-19941

Furaprevir	HCV Protease	Infection
Furaprevir is a potent and selective **HCV NS3/4A protease** inhibitor. Furaprevir can be used for genotype 1 hepatitis C research .

HY-N8520

Variculanol	Bacterial	Infection Cancer
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .

HY-108018

MK 6325	HCV Protease	Infection
MK 6325 is a **HCV NS3/4a protease** inhibitor. MK 6325 displays the broad genotype and mutant potency. MK 6325 can be used for the research of infection .

HY-15256A

Faldaprevir sodium BI 201335 sodium	HCV Protease	Infection
Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .

HY-10235R

Telaprevir (Standard) VX-950 (Standard)	Reference Standards HCV Protease HCV SARS-CoV	Infection
Telaprevir (Standard) is the analytical standard of Telaprevir. This product is intended for research and analytical applications. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-12594A

Paritaprevir dihydrate ABT-450 dihydrate; Veruprevir dihydrate	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-12594R

Paritaprevir (Standard) ABT-450 (Standard); Veruprevir (Standard)	HCV Protease HCV SARS-CoV Reference Standards	Infection
Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-115516

BI-1388	HCV HCV Protease Ras	Infection
BI-1388 is a macrocyclic acylsulfonamide-based *HCV* *NS3-4A* protease inhibitor. BI-1388 inhibits clinically relevant drug-resistant mutant strains (KRAS ^D168V gt 1b and KRAS ^R155K gt 1a) and exhibits high liver distribution. BI-1388 is applicable for the research of HCV infection .

HY-10238R

Danoprevir (Standard) ITMN-191 (Standard); R7227 (Standard); RO5190591 (Standard); RG7227 (Standard)	Reference Standards HCV Protease HCV SARS-CoV	Infection
Danoprevir (Standard) is the analytical standard of Danoprevir (HY-10238). This product is intended for research and analytical applications. Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM) . Danoprevir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 0.05 μM .

HY-108029

Deldeprevir sodium ACH-2684 sodium; Neceprevir sodium	HCV HCV Protease	Infection
Deldeprevir (ACH-2684; Neceprevir) sodium is a **HCV NS3/4A** protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b *HCV, including mutant strains resistant to other NS3* protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .

HY-10241R

Simeprevir (Standard) TMC435 (Standard); TMC435350 (Standard)	Reference Standards HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (Standard) is the analytical standard of Simeprevir (HY-10241). This product is intended for research and analytical applications. Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8520

Variculanol	Microorganisms Terpenoids Sesquiterpenes Source Classification	Bacterial
Variculanol is an antimicrobial, anticancer and anti-HCV NS3/4A Protease agent which can be extracted from marine fungus Aspergillus versicolor .

Cat. No.	Product Name	Chemical Structure

HY-10241S

Simeprevir-13C,d3
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-131905S

BMS-986144
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks